News | October 12, 2025
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Medico Remedies receives order worth US$ 1,781,000
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Subscribe To Our Newsletter & Stay Updated
